Biotech Gainers to Watch: Vanda Pharmaceuticals (NASDAQ:VNDA), Cytokinetics, Incorporated (NASDAQ:CYTK), BioCryst Pharmaceuticals (NASDAQ:BCRX), JUNO THERAPEUTICS (NASDAQ:JUNO), Sorrento Therapeutics (NASDAQ:SRNE)


Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) recently announced that it has reached a settlement agreement with Novartis AG related to Fanapt. Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) in last trading activity advanced 8.17% to close at $14.69. Company weekly performance is 14.68% while its quarterly performance stands at 36.14%. Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) is -23.69% away from its 52 week high.

On December 22, 2014, Cytokinetics, Incorporated (NASDAQ:CYTK) entered into an Amended and Restated Collaboration and License Agreement (the “Amended Agreement”) with Astellas Pharma Inc. (“Astellas”), replacing in full the Collaboration and License Agreement entered into between the Company and Astellas on June 21, 2013 (the “Original Agreement”). The Amended Agreement expands the objective of the collaboration of advancing novel therapies for diseases and medical conditions associated with muscle weakness to now include spinal muscle atrophy (“SMA”) and potentially other neuromuscular indications, in addition to the non-neuromuscular indications provided for in the Original Agreement.On last trading day Cytokinetics, Incorporated (NASDAQ:CYTK) advanced 6.34% to close at $5.87. Its volatility for the week is 5.15% while volatility for the month is 5.88%. CYTK’s sales growth for past 5 years was 19.80% and its EPS growth for past 5 years was 29.00%. Cytokinetics, Incorporated (NASDAQ:CYTK) monthly performance is 32.81%.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that the FDA has granted orphan drug designation to BCX4161 for the prevention of acute attacks of angioedema in patients with hereditary angioedema (HAE).On last trading day BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) advanced 6.87% to close at $11.83. Its volatility for the week is 6.68% while volatility for the month is 6.32%. BCRX’s sales growth for past 5 years was -21.10% and its EPS growth for past 5 years was 3.30%. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) monthly performance is 11.39%.

Juno Therapeutics Inc. (NASDAQ:JUNO) major shareholder Douglas K. Bratton bought 625,000 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were purchased at an average price of $24.00 per share, for a total transaction of $15,000,000.00. JUNO THERAPEUTICS, INC. (NASDAQ:JUNO) stock closed at $39.99.

HC Wainright set a $11.00 price target on Sorrento Therapeutics (NASDAQ:SRNE) in a research report sent to investors on Friday morning. The firm currently has a buy rating on the stock. On Wednesday shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) closed at $9.50.


Leave a Reply

Your email address will not be published. Required fields are marked *